Treats moderate acne vulgaris in females at least 15 years of age. ANDA 200494, held by Glenmark Pharms Ltd. Ethinyl Estradiol; Norgestimate, Norgestimate; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 200494 (Norgestimate And Ethinyl Estradiol, Norgestimate; Ethinyl Estradiol), held by Glenmark Pharms Ltd, was first approved by FDA on Jun 17, 2011, with 7 approved supplements and 0 published complete response letters.
Norgestimate and ethinyl estradiol tablets are estrogen/progestin COCs, indicated for use by women to prevent pregnancy. Norgestimate and ethinyl estradiol tablets 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg are also indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Norgestimate and ethinyl estradiol tablets 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. 1.1 Oral Contraceptive Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 17, 2011 | Original application | Approved | None posted |
| Norgestimate And Ethinyl Estradiol0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Norgestimate; Ethinyl Estradiol0.215MG; 0.035MG · tablet; oral | Norgestimate; Ethinyl Estradiol | Rx |
| Norgestimate; Ethinyl Estradiol0.25MG; 0.035MG · tablet; oral | Norgestimate; Ethinyl Estradiol | Rx |
| Feb 22, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 26, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 26, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 28, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 28, 2012 | Supplement 2Labeling | Approved | None posted |
| Jun 17, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters